July 26th, 2024
United Immunity enters into the Research Collaboration Agreement with AstraZeneca
United Immunity (Tokyo, Japan) enters into the Research Collaboration Agreement with AstraZeneca.
See further information on the Japanese press release.
(https://www.astrazeneca.co.jp/media/press-releases1/2024/2024072601.html)
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting PlatformTM .